DK2115478T3 - Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som prædiktiv markør for cardiovaskulære sygdomme - Google Patents

Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som prædiktiv markør for cardiovaskulære sygdomme Download PDF

Info

Publication number
DK2115478T3
DK2115478T3 DK07858108.9T DK07858108T DK2115478T3 DK 2115478 T3 DK2115478 T3 DK 2115478T3 DK 07858108 T DK07858108 T DK 07858108T DK 2115478 T3 DK2115478 T3 DK 2115478T3
Authority
DK
Denmark
Prior art keywords
supar
risk
years
marker
individuals
Prior art date
Application number
DK07858108.9T
Other languages
English (en)
Inventor
Jesper Eugen-Olsen
Steen B Haugaard
Ove Andersen
Original Assignee
Hvidovre Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvidovre Hospital filed Critical Hvidovre Hospital
Application granted granted Critical
Publication of DK2115478T3 publication Critical patent/DK2115478T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

1. Fremgangsmåde til at bestemme risikoen for udvikling af cardiovaskulær sygdom i et pattedyr (fx et menneske)-individ der tilsyneladende er raskt, hvilken fremgangsmåde omfatter: (a) udføre en in wfro-måling af niveauet af en markør i form af (i) opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) og/eller (ii) D2D3 kløvningsprodukter af suPAR, i én eller flere prøver omfattende en biologisk væske opnået fra individet, eventuelt opnået ved forskellige tidspunkter og (b) anvende den ene eller flere målte værdier opnået som en faktor i bestemmelsen, fx ved hjælp af sammenligning med en referenceværdi.
2. Fremgangsmåde ifølge krav 1, endvidere omfattende sammenligning af den bestemte risiko ved ét eller flere tidspunkter for teste virkningen af et profylaktisk virkningsforløb (for eksempel, fysisk motion) og/eller behandling.
3. Fremgangsmåde ifølge krav 2, hvor markørens niveau er aftaget med mindst ca. 10% og/eller 1 ng/ml.
4. Fremgangsmåden ifølge krav 1, hvor en stigning på mindst ca. 10% og/eller 1 ng/ml i markøren i prøven sammenlignet med reference prøven bliver taget som en indikation på en øget risiko for sygdom.
5.
Fremgangsmåden ifølge krav 1, hvor fremgangsmåden yderligere omfatter at udføre en glucosetolerencetest, og/eller teste TNF-alfa, IL-6, leukocyttælling, fastende plasma-glucose eller fastende blod-glucose, blodtryk, kolesterol, C-reaktiv protein- og/eller triglyceridniveauer.
DK07858108.9T 2006-12-22 2007-12-21 Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som prædiktiv markør for cardiovaskulære sygdomme DK2115478T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87683806P 2006-12-22 2006-12-22
DKPA200601709 2006-12-22
US94707407P 2007-06-29 2007-06-29
DKPA200700956 2007-06-29
PCT/EP2007/064497 WO2008077958A2 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (supar) as marker for diseases

Publications (1)

Publication Number Publication Date
DK2115478T3 true DK2115478T3 (da) 2014-03-10

Family

ID=39358030

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07858108.9T DK2115478T3 (da) 2006-12-22 2007-12-21 Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som prædiktiv markør for cardiovaskulære sygdomme
DK12164660.8T DK2500730T3 (da) 2006-12-22 2007-12-21 Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som diagnostisk markør for en lavgrad-inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12164660.8T DK2500730T3 (da) 2006-12-22 2007-12-21 Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som diagnostisk markør for en lavgrad-inflammation

Country Status (15)

Country Link
US (2) US8815519B2 (da)
EP (2) EP2115478B1 (da)
AU (1) AU2007337996B2 (da)
CA (1) CA2674521C (da)
CY (1) CY1120296T1 (da)
DK (2) DK2115478T3 (da)
ES (2) ES2456043T3 (da)
GB (1) GB2461410C (da)
HU (1) HUE037758T2 (da)
LT (1) LT2500730T (da)
PL (1) PL2500730T3 (da)
PT (1) PT2500730T (da)
SI (1) SI2500730T1 (da)
TR (1) TR201807733T4 (da)
WO (1) WO2008077958A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
CA2779958A1 (en) * 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8349256B2 (en) * 2008-11-21 2013-01-08 Sysmex Corporation Blood cell analyzer, blood cell analyzing method, and computer program product
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
ES2765006T3 (es) 2011-05-09 2020-06-05 The Univ Of Miami Reducción del receptor soluble de urocinasa en la circulación
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
WO2014012043A1 (en) * 2012-07-13 2014-01-16 Baylor Research Institute Urinary triaosylceramide (gb3) as a risk factor in non-fabry heart disease subjects
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
WO2016201573A1 (en) * 2015-06-16 2016-12-22 Quantum Dental Technologies Inc. System and method of monitoring consumable use based on correlations with diagnostic testing
WO2017075268A1 (en) 2015-10-27 2017-05-04 Abbott Laboratories Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease
FI20177098A1 (fi) 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
GB201802795D0 (en) 2018-02-21 2018-04-04 Virogates As Patient assessment method
RU2706548C1 (ru) * 2019-01-31 2019-11-19 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики стадий вич-инфекции
WO2020206129A1 (en) * 2019-04-02 2020-10-08 The Regents Of The University Of Michigan Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease
CN111128398B (zh) * 2020-03-30 2020-08-14 广州地理研究所 一种基于人口迁徙大数据的流行病感染人数估算方法
CN115516314A (zh) 2020-04-08 2022-12-23 维罗盖茨有限公司 Sars-cov-2感染风险评估方法
CN112630442A (zh) * 2020-11-03 2021-04-09 浙江大学 一种血浆可溶性尿激酶型纤溶酶原激活物受体及其应用
EP4490511A2 (en) * 2022-03-07 2025-01-15 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN114334170A (zh) * 2022-03-14 2022-04-12 天津云检医学检验所有限公司 一种代谢年龄预测模型及其在结直肠癌诊断中的应用
CN114783607B (zh) * 2022-05-10 2023-06-23 中南大学湘雅医院 一种手术输血风险预测模型及其网络计算器的构建方法
CN116106535B (zh) * 2023-04-11 2023-08-11 南京品生医学检验实验室有限公司 生物标志物组合在制备乳腺癌预测产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033653T2 (de) * 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
ES2291226T3 (es) * 1999-11-25 2008-03-01 Jesper Eugen-Olsen Un metodo de diagnostico o prognosis de infeccion por vih en un sujeto.
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
PT1765397E (pt) 2004-05-25 2013-02-04 Tactic Pharma Llc Anticorpos inibidores que se ligam ao complexo ativador plasminogénico do tipo uroquinasa (upa) e seu receptor (upar)
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases

Also Published As

Publication number Publication date
GB0912351D0 (en) 2009-08-26
HUE037758T2 (hu) 2018-09-28
LT2500730T (lt) 2018-05-10
ES2456043T3 (es) 2014-04-21
US9645157B2 (en) 2017-05-09
GB2461410C (en) 2018-06-20
CA2674521C (en) 2022-06-14
WO2008077958A2 (en) 2008-07-03
SI2500730T1 (en) 2018-08-31
PL2500730T3 (pl) 2018-08-31
EP2500730B1 (en) 2018-03-07
WO2008077958A3 (en) 2009-04-02
CA2674521A1 (en) 2008-07-03
EP2115478B1 (en) 2014-01-22
US20100098705A1 (en) 2010-04-22
AU2007337996A1 (en) 2008-07-03
EP2115478A2 (en) 2009-11-11
US8815519B2 (en) 2014-08-26
GB2461410B (en) 2011-06-29
TR201807733T4 (tr) 2018-06-21
EP2500730A1 (en) 2012-09-19
GB2461410A (en) 2010-01-06
PT2500730T (pt) 2018-05-28
DK2500730T3 (da) 2018-05-28
ES2670711T3 (es) 2018-05-31
CY1120296T1 (el) 2019-07-10
AU2007337996B2 (en) 2013-03-14
US20140370527A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
DK2115478T3 (da) Opløselig urokinase-plasminogen-aktivatorreceptor (suPAR) som prædiktiv markør for cardiovaskulære sygdomme
EP3030901B1 (en) Methods and kits for predicting the risk of having a cardiovascular event
Le et al. The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes
US11598781B2 (en) Method for predicting the risk of incidence of chronic kidney disease
Boutari et al. Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
AU2013200398B2 (en) Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Marker for Diseases
El-Hady et al. Serum ferritin, transferrin and metabolic syndrome are risk factors for subclinical atherosclerosis in Egyptian women with systemic lupus erythematosus (SLE)
US20240272178A1 (en) A method for predicting sepsis and septic shock
JP6116938B2 (ja) 新規な肺高血圧症のマーカー
EP3985396A1 (en) Prognosis prediction method of idiopathic pulmonary fibrosis
WO2025132799A1 (en) Methods for diagnosis and monitoring nash disease
KR20220158754A (ko) 간 섬유증의 비침습적 진단 방법
HK40016117A (en) A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
US20150104463A1 (en) Methods and kits for predicting the risk of having a cardiovascular event in a subject